On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was 23.88% up from the session before settling in for the closing price of $8.50. A 52-week range for RXRX has been $5.60 – $15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 132.77% over the past five years. When this article was written, the company’s average yearly earnings per share was at 2.61%. With a float of $296.92 million, this company’s outstanding shares have now reached $390.76 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 17.35%, while institutional ownership is 61.88%. The most recent insider transaction that took place on Feb 06 ’25, was worth 162,400. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $8.12, taking the stock ownership to the 1,273,156 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Executive Officer sold 20,000 for $7.68, making the entire transaction worth $153,600. This insider now owns 1,273,156 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.49% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 63.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 39.75 million, a positive change from its year-to-date volume of 22.68 million. As of the previous 9 days, the stock’s Stochastic %D was 96.60%. Additionally, its Average True Range was 0.81.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 95.64%, which indicates a significant increase from 94.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.58% in the past 14 days, which was higher than the 93.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.29, while its 200-day Moving Average is $7.44. Nevertheless, the first resistance level for the watch stands at $11.18 in the near term. At $11.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.89. If the price goes on to break the first support level at $9.46, it is likely to go to the next support level at $8.39. Assuming the price breaks the second support level, the third support level stands at $7.75.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are 390,722K outstanding shares of the company, which has a market capitalization of 4.11 billion. As of now, sales total 44,580 K while income totals -328,070 K. Its latest quarter income was 26,080 K while its last quarter net income were -95,840 K.
